<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>Research and Enterprise</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/46AEDCA7-EE1E-463E-B540-243E29D0747E"><gtr:id>46AEDCA7-EE1E-463E-B540-243E29D0747E</gtr:id><gtr:firstName>Iseabail</gtr:firstName><gtr:otherNames>Mhairi</gtr:otherNames><gtr:surname>Macrae</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3C8A544E-00F6-4FA9-B14D-1F04B5B50A56"><gtr:id>3C8A544E-00F6-4FA9-B14D-1F04B5B50A56</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BD6339DF-6706-4458-ACAD-49C246900497"><gtr:id>BD6339DF-6706-4458-ACAD-49C246900497</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>F</gtr:otherNames><gtr:surname>Dominiczak</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400052"><gtr:id>83E86C87-140B-43FB-BF2C-26A1ADB9E575</gtr:id><gtr:title>Targeted Gene Therapy For Cardiovascular Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400052</gtr:grantReference><gtr:abstractText>This proposal is timely since the recent Department of Health white paper encouraged translational research in gene therapy. This is particularly relevant to this proposal since we are expanding our molecular understanding of disease and engineering novel genetic medicines. 
Gene therapy is relatively high profile and public education is very important. In the light of recent events (e.g. SCID) public engagament is critical as we begin to treat patients with genetic medicines. For our proposal this is very important since target patient populations are large and education aimed at understanding gene therapy will be essential. The applicants are very active in this area through our host University and through existing funding councils. In addition, the newly formed British Society for Gene Therapy (www.bsgt.org) has in its consititution the role of BSGT in public education. AHB is a founder member and treasurer of BSGT and hence this will maximise public engagement in the technology and applications of gene therapy. Additionally, during the fundraising campaign for the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC) AFD has been giving regular talks to lay audiences on genetics and cardiovascular disease.</gtr:abstractText><gtr:technicalSummary>Gene therapy remains a realistic treatment option for diverse cardiovascular diseases and provides an invaluable tool for probing molecular mechanisms of disease in pre-clinical models. The mode of gene delivery, the transgene cassette and the longevity of transgene expression in vivo are all critical factors to maximise clinical benefit. Here, we systematically evaluate modified gene delivery vectors based on adenovirus and adeno-associated vector technology and apply this to acute and chronic models of cardiovascular disease. Our programme of work is to rationally construct and characterise a panel of designer gene delivery vectors for cardiovascular gene therapy. We will identify targeting peptides to diseased tissue in a clinically relevant model of cardiovascular disease, the stroke-prone spontaneously hypertensive rat. Subsequently, we will construct a panel of transductionally targeted Ad and AAV vectors incorporating homing peptides in viral capsids that will allow systemic targeting to site(s) of disease. We will focus on first-generation and helper-dependent Ad vectors as well as AAV vectors in order to afford acute and long-term transgene overexpression profiles. Biodistribution profiling will be performed using high throughput Taqman technology. The impact of targeted overexpression of candidate therapeutic genes on phenotypic outcomes in the disease models that include endothelial dysfunction, stroke and myocardial infarction will then be evaluated using a range of techniques including immunohistochemistry, functional studies and MRI. Our programme of work will fully evaluate the unique potential of targeted gene therapy for defined cardiovascular diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>365685</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lawrence Chan</gtr:description><gtr:id>1D20536C-C980-447E-A74E-A7B833A8EE71</gtr:id><gtr:impact>JCI paper</gtr:impact><gtr:outcomeId>049195D4E30-1</gtr:outcomeId><gtr:partnerContribution>paper</gtr:partnerContribution><gtr:piContribution>new research tools</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>gtac</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>03744012-21D8-4CD7-8D51-EC024AAEAD69</gtr:id><gtr:impact>open day

interaction with school children</gtr:impact><gtr:outcomeId>BFD4F7203D5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>950246DF-2BF2-4F6D-81DB-E1F7B59816F6</gtr:id><gtr:title>Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edd0f95ba03421e630b6876d82205f2"><gtr:id>3edd0f95ba03421e630b6876d82205f2</gtr:id><gtr:otherNames>Kritz AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>318C78386F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE985FF1-926E-446C-A3F7-BEC07B1457EA</gtr:id><gtr:title>Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbdb1289ee0a4fb89e55f47bbd237dd8"><gtr:id>cbdb1289ee0a4fb89e55f47bbd237dd8</gtr:id><gtr:otherNames>Nicol CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>4082897CFA0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400052</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>